Innovating Works

FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER

Activa
PROMINENT: PRECISION MEDICINE PLATFORM IN NEURODEGENERATIVE DISEASE KAROLINSKA INSTITUTET tramitó un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-01 Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million...
2023-04-25 - 2028-04-30 | Financiado
HeBe: Identification of age related Human Blood factors as a therapeutic target for Alzheimer s disease FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER tramitó un H2020: ERC-2020-STG One of the most exciting findings in neuroscience has been the discovery of peripheral blood factors with rejuvenating or ageing effects on...
2020-11-10 - 2026-03-31 | Financiado
BioALFA: The effect of pro aging and pro youthful blood factors in normal ageing and Alzheimer s disease a m... FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER tramitó un H2020: MSCA-IF-2016 The overall aim of the planned research is to test whether pro-aging and pro-youthful blood factors are associated with cognitive performanc...
2017-03-21 - 2020-01-14 | Financiado
AMYPAD: Amyloid imaging to Prevent Alzheimer s Disease Sofia ref. 115952 STICHTING AMSTERDAM UMC tramitó un H2020: IMI2-2015-05-04 Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD)...
2016-11-08 - 2022-09-30 | Financiado
NPAD: Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer s Disease FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER tramitó un H2020: MSCA-IF-2015-EF This project aims at predicting early cognitive decline using a neurofeedback performance endophenotype based on realtime functional magneti...
2016-04-04 - 2018-05-13 | Financiado
EPAD: European Prevention of Alzheimer’s Dementia Consortium JANSSEN PHARMACEUTICA NV tramitó un FP6: Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression...
2015-01-01 - 2019-12-31 | Financiado
AETIONOMY: Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of... UCB BIOPHARMA tramitó un FP6: IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this ca...
2014-01-01 - 2018-12-31 | Financiado
EPAD: European Prevention of Alzheimer s Dementia Consortium JANSSEN PHARMACEUTICA NV tramitó un FP7: Background: The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progressio...
Financiado
AETIONOMY: Aetionomy Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of... UCB BIOPHARMA tramitó un FP7: IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this ca...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.